Last reviewed · How we verify
Experimental drug: Aprepitant
Aprepitant blocks neurokinin-1 (NK1) receptors in the brain to prevent nausea and vomiting.
Aprepitant blocks neurokinin-1 (NK1) receptors in the brain to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy, Post-operative nausea and vomiting (PONV) prevention.
At a glance
| Generic name | Experimental drug: Aprepitant |
|---|---|
| Sponsor | CCTU |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology / Supportive Care |
| Phase | Phase 3 |
Mechanism of action
Aprepitant is a selective antagonist of the neurokinin-1 (NK1) receptor, which plays a key role in the chemoreceptor trigger zone and vomiting center. By crossing the blood-brain barrier and occupying NK1 receptors, it prevents the transmission of emetic signals triggered by chemotherapy and other emetogenic stimuli. This mechanism is particularly effective for delayed chemotherapy-induced nausea and vomiting (CINV).
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
- Post-operative nausea and vomiting (PONV) prevention
Common side effects
- Fatigue
- Headache
- Constipation
- Diarrhea
- Hiccups
Key clinical trials
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide (PHASE4)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients (PHASE3)
- Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence (PHASE2)
- An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental drug: Aprepitant CI brief — competitive landscape report
- Experimental drug: Aprepitant updates RSS · CI watch RSS
- CCTU portfolio CI